Lakewood-Amedex Biotherapeutics (LABT) Registration filing summary

Company overview and business model

• Focuses on developing novel antimicrobial therapeutics targeting infectious diseases, especially those driven by antimicrobial resistance (AMR).

• Lead product, Nu-3, is a broad-spectrum Bisphosphocin® antimicrobial for topical treatment of infected diabetic foot ulcers (iDFU).

• Pipeline includes additional Bisphosphocin® compounds for urinary tract and pulmonary infections.

• Holds 68 issued and 36 pending patents covering core technologies and product candidates in major pharmaceutical markets.

• Operates as a capital-efficient, outsourced model, relying on third-party manufacturers for clinical and commercial supply.

Financial performance and metrics

• No revenue from product sales to date; operations funded by $46.1 million in gross proceeds from equity and convertible debt.

• Net loss of $4.9 million for 2024 and $8.3 million for 2023; accumulated deficit of $52.6 million as of September 30, 2025.

• Cash and cash equivalents of $0.7 million as of September 30, 2025.

• Research and development expenses were $2.1 million in 2024, down from $5.5 million in 2023.

• General and administrative expenses were $1.9 million in 2024, down from $3.1 million in 2023.

• Significant going concern risk disclosed by auditors due to recurring losses and limited cash.

Use of proceeds and capital allocation

• Proceeds from Series C Preferred Stock financing ($7.5 million) intended to fund completion of Phase 2a clinical trial for Nu-3 gel and support ongoing operations.

• Net proceeds allocated to clinical development, preclinical pipeline advancement, regulatory submissions, and operational expansion.

• No proceeds from the direct listing will go to the company; all proceeds from registered shares will go to selling shareholders.